{"id":60130,"date":"2024-10-07T04:04:45","date_gmt":"2024-10-07T02:04:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/"},"modified":"2024-10-07T04:04:45","modified_gmt":"2024-10-07T02:04:45","slug":"hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/","title":{"rendered":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024"},"content":{"rendered":"
\n

CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C. & SEOUL, Korea–(BUSINESS WIRE)–Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five major international conferences this fall. With a strategic focus on securing global licensing partnerships, Shaperon and Hudson Therapeutics will actively promote its innovative clinical programs addressing significant unmet needs in atopic dermatitis, alopecia areata, and idiopathic pulmonary fibrosis, an orphan indication <\/b>for human and animal health.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nHudson Therapeutics and Shaperon will engage in the following events:\n<\/p>\n

\n– Animal Health, Nutrition and Technology Innovation Asia 2024 \u2013 October 7 \u2013 8, 2024 \/ Tokyo, Japan\n<\/p>\n

\n– Bio Japan | Regenerative Medicine Japan | HealthTech Japan \u2013 October 9 \u2013 11, 2024 \/ Tokyo, Japan\n<\/p>\n

\n– Pharm Partnering Summit \u2013 October 16 \u2013 17, 2024 \/ Boston, MA USA\n<\/p>\n

\n– Bio Europe \u2013 November 4 \u2013 6, 2024 \/ Stockholm Sweden\n<\/p>\n

\n– 8th<\/sup> Dermatology Drug Development Summit \u2013 Number 12, 14, 2024\n<\/p>\n

\n\u201cAt these key conferences, we aim to take a leading role in advancing our innovative therapeutic solutions, not just for humans but for veterinary medicine as well,\u201d said Dr. Seung-Yong Seong, CEO of Shaperon. \u201cBy actively engaging with potential global partners, we intend to accelerate the commercialization and global distribution of our programs targeting idiopathic pulmonary fibrosis, alopecia areata<\/b>, and atopic dermatitis<\/b>, addressing clinical unmet needs in these areas.\u201d\n<\/p>\n

\nMs. Janice Marie McCourt, CEO of Hudson Therapeutics<\/b>, reinforced this initiative: \u201cThese conferences offer invaluable opportunities to drive strategic collaborations. We are actively seeking partnerships to help us bring our NanoMab-based therapies to market globally, enhancing treatment options for inflammatory and fibrotic diseases in humans and companion animals.\u201d\n<\/p>\n

\nHudson Therapeutics and Shaperon are committed to positioning themselves at the forefront of innovation by actively pursuing global licensing strategies and building strong early-stage collaborations. This initiative-taking approach ensures their leadership in the rapidly growing autoimmune and inflammatory disease sectors\n<\/p>\n

\nAccording to The DATA Bridge Market Research, the global market for Alopecia Areata Treatment is projected to grow from $9.58 billion in 2024 to $17.93 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 17.93%.\n<\/p>\n

\nHudson Therapeutics invites interested parties to discuss partnership opportunities during the upcoming events.\n<\/p>\n

\nABOUT SHAPERON<\/b>\n<\/p>\n

\nShaperon is a clinical stage biotech company developing novel inflammasome inhibitors. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1\u03b2, IL-18, IL-6, and TNF-\u03b1 by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, alopecia areata, alzheimer\u2019s disease, and COVID 19 pneumonia in addition to pre-clinical pipeline assets, focused in MASH and obesity therapeutic areas.\n<\/p>\n

\nABOUT Hudson Therapeutics<\/b>\n<\/p>\n

\nHudson Therapeutics, a US subsidiary of Shaperon was founded and incorporated in the US in 2023 to lead global clinical trials, investor relations, commercial strategy, and business development of assets from Shaperon. Hudson also plans to develop Shaperon’s early-stage assets in the future.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information or to schedule a meeting, please contact:
\n
Ellie Jung, Chief Communications and Administrative Officer
\n
Email: ellie@hudsontherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C. & SEOUL, Korea–(BUSINESS WIRE)–Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five major international conferences this fall. With a strategic focus on securing global licensing partnerships, Shaperon and Hudson Therapeutics will actively promote … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60130","6":"format-standard","7":"category-industry"},"yoast_head":"\nHudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C. & SEOUL, Korea–(BUSINESS WIRE)–Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five major international conferences this fall. With a strategic focus on securing global licensing partnerships, Shaperon and Hudson Therapeutics will actively promote ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-07T02:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024\",\"datePublished\":\"2024-10-07T02:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/\"},\"wordCount\":525,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241006658150\\\/en\\\/2264417\\\/22\\\/base_logo_transparent_background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/\",\"name\":\"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241006658150\\\/en\\\/2264417\\\/22\\\/base_logo_transparent_background.jpg\",\"datePublished\":\"2024-10-07T02:04:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241006658150\\\/en\\\/2264417\\\/22\\\/base_logo_transparent_background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241006658150\\\/en\\\/2264417\\\/22\\\/base_logo_transparent_background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/","og_locale":"en_US","og_type":"article","og_title":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend","og_description":"CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C. & SEOUL, Korea–(BUSINESS WIRE)–Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five major international conferences this fall. With a strategic focus on securing global licensing partnerships, Shaperon and Hudson Therapeutics will actively promote ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-07T02:04:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024","datePublished":"2024-10-07T02:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/"},"wordCount":525,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/","url":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/","name":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg","datePublished":"2024-10-07T02:04:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241006658150\/en\/2264417\/22\/base_logo_transparent_background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hudson-therapeutics-and-shaperon-to-actively-pursue-global-licensing-partnerships-at-key-industry-conferences-in-q4-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Hudson Therapeutics and Shaperon to Actively Pursue Global Licensing Partnerships at Key Industry Conferences in Q4 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60130"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60130\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}